NASVAC is delivered through nasal spray and in phase I trial was found to be safe and tolerable. All subjects developed anti-HBc antibody at days 30 after immunization, with 75% developing anti-HBs antibody of more than or equals 10 IU/L at a maximum at days 90[68]. The phase III trial to evaluate the therapeutic effects on lowering HBV DNA and other clinically important parameters is presently being conducted.
发表于 2015-8-11 19:53
真的假的？